Cover Page
The handle http://hdl.handle.net/1887/25850 holds various files of this Leiden University dissertation
Author: Beek, Erik te
Title: Neuropharmacology of novel dopamine modulators
Issue Date: 2014-06-03
curriculum vitae – 173 –
curriculum vitae
Erik te Beek was born in Naarden on September 26th in 1975. After graduation
from medical school in 2003 at the University of Amsterdam, he worked as a resi-
dent in neurosurgery at the Slotervaartziekenhuis in Amsterdam and later as a
resident in neurology at the Kennemer Gasthuis in Haarlem. In between, he also
worked as a research physician at the neurogenetics laboratory of the Academic
Medical Center in Amsterdam. From 2007 until 2010, he worked as a research
physician at the Centre for Human Drug Research in Leiden. The research de-
scribed in this thesis was performed in that period. During the same period, he
was also trained as clinical pharmacologist. In January 2011, he started as a resi-
dent in nuclear medicine at the Leids Universitair Medisch Centrum in Leiden.
neuropharmacology of novel dopamine modulators – 174 –
list of publications – 175 –
list of publications
1 Boer GJ, Van Esseveldt KE, Dijkhuizen PA, Hermens W.T., Te Beek ET, Van Heerikhuize JJ, Poldervaart HA, Verhaagen J (2001) Adenoviral vector-mediated expression of neurotrophin-3 increases neuronal survival in suprachiasmatic nucleus grafts. Exp Neurol 169: 364-375
2 Ruitenberg MJ, Blits B, Dijkhuizen PA, Te Beek ET, Bakker A, Van Heerikhuize JJ, Pool CW, Hermens WT, Boer GJ, Verhaagen J (2004) Adeno-associated viral vector-mediated gene transfer of brain- derived neurotrophic factor reverses atrophy of rubrospinal neurons following both acute and chronic spinal cord injury. Neurobiol Dis 15: 394-406 3 Budde BS, Namavar y, Barth PG, Poll-The BT,
Nürnberg G, Becker C, Van Ruissen F, Weterman MAJ, Fluiter K, Te Beek ET, Aronica E, Van der Knaap MS, Höhne W, Toliat MR, Crow yJ, Steinlin M, Voit T, Roelens F, Brussel W, Brockmann K, Kyllerman M, Boltshauser E, Hammersen G, Willemsen M, Basel-Vanagaite L, Krägeloh-Mann I, De Vries LS, Sztriha L, Muntoni F, Ferrie CD, Battini R, Hennekam RC, Grillo E, Beemer FA, Stoets LM, Wollnik B, Nürnberg P, Baas F (2008) tRNA splicing endonuclease mutations cause pontocerebellar hypoplasia. Nature Genetics 40:
1113-1118
4 Liem-Moolenaar M, Te Beek ET, De Kam ML, Franson KL, Kahn RS, Hijman R, Touw D, Van Gerven JM (2010) Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol 24: 1697-1708
5 Jepma M, Te Beek ET, Wagenmakers EJ, Van Gerven JM, Nieuwenhuis S (2010) The role of the noradrenergic system in the exploration- exploitation trade-off: a psychopharmacological study. Front Hum Neurosci 4: 170
6 Te Beek ET, Zoethout RW, Bani MS, Andorn A, Iavarone L, Klaassen ES, Fina P, Van Gerven JM (2012) Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist gsk598809 and intravenous alcohol infusion at pseudo-steady state. J Psychopharmacol 26: 303-314
7 Te Beek ET, Moerland M, De Boer P, Van Nueten L, De Kam ML, Burggraaf J, Cohen AF, Van Gerven JM (2012) Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist jnj-37822681. J Psychopharmacol 26:
1119-1127
8 Te Beek ET, De Boer P, Moerland M, Schmidt ME, Hoetjes NJ, Windhorst AD, Van Berckel BN, Cohen AF, Van Gerven JM, Lammertsma AA (2012) In vivo quantification of striatal dopamine D2 receptor occupancy by jnj-37822681 using [11C]
raclopride and positron emission tomography. J Psychopharmacol 26: 1128-1135
9 Klumpers LE, Cole DM, Khalili-Mahani N, Soeter RP, Te Beek ET, Rombouts SA, Van Gerven JMA (2012) Manipulating brain connectivity with δ9- tetrahydrocannabinol: a pharmacological resting state FMRI study. NeuroImage 63: 1701-1711 10 Hoch M, Hay JL, Hoever P, De Kam ML, Te Beek ET,
Van Gerven JM, Dingemanse J (2013) Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol. Eur Neuro- psychopharmacol 23: 107-117
11 Te Beek ET, Hay JL, Bullman JN, Burgess C, Nahon KJ, Klaassen ES, Gray FA, Van Gerven JM (2013) Pharmacokinetics and central nervous system effects of the novel dual NK1/NK3 receptor an- tagonist GSK1144814 in alcohol-intoxicated volun- teers. Br J Clin Pharmacol 75: 1328-1339
12 Te Beek ET, Tatosian D, Majumdar A, Selverian D, Klaassen ES, Petty KJ, Gargano C, Van Dyck K, McCrea J, Murphy G, Van Gerven JM (2013) Pla- cebo- and amitriptyline-controlled evaluation of central nervous system effects of the NK1 receptor antagonist aprepitant and intravenous alcohol infusion at pseudo-steady state. J Clin Pharmacol 53:
846-85
neuropharmacology of novel dopamine modulators – 176 –
samenvatting – 177 –
